Constantiam Biosciences

What started as three friends at the University of Wisconsin-Madison, pursuing different paths and careers has now evolved into Constantiam Biosciences—a company driven by shared passion to make a difference in the world of genetic testing and precision medicine. 🧬 Nicholas S. ’08, Daniel Goldman ’07, and Norman Kuok Ong, PhD, CLP ’07, have stayed in touch for years, bringing together their diverse experiences to build something truly special. This journey reached a major milestone when we were awarded a $2M Phase II SBIR grant from the National Human Genome Research Institute (NHGRI) in June 2024. This grant is fueling our mission to transform genetic testing by resolving Variants of Uncertain Significance (VUS), bringing clarity to patients and clinicians across cancer, cardiovascular, and neurodegenerative diseases. We’re excited that the UW Alumni Association highlighted this achievement, showcasing the power of lifelong connections forged at UW-Madison. From the classrooms to the forefront of biotech innovation, this journey is a testament to friendship, collaboration, and a shared vision to make a meaningful impact in healthcare. Here’s to pushing the boundaries of science and friendship! 🚀 Learn more: https://lnkd.in/dq3P269m #UWAlumni #GeneticTesting #PrecisionMedicine #ConstantiamBiosciences #NHGRI #HealthcareInnovation

Breast cancer is more than a diagnosis—it's a journey that requires strength, support, and unwavering hope. At Constantiam Biosciences, we are committed to ensuring that no patient or family faces this battle without answers. Through advanced genetic testing and precision medicine, we are dedicated to providing the clarity and insights that empower both patients and clinicians to make informed decisions. With every variant we resolve, we move closer to a future where uncertainty no longer adds to the burden. Our mission is simple: to ensure that no one fights this battle in the dark. Together, we turn uncertainty into action, ensuring no one walks this road alone. 💪 #Pinktober #NoOneShouldFaceBreastCancerAlone #BreastCancerAwareness #GeneticTesting #PrecisionMedicine #ConstantiamBiosciences #HealthcareInnovation #SupportTheFighters

Work hard, bowl harder! 🎳 From team meetings by day to strikes by night, we know how to balance work with a little fun. 🧠➡️🎳

Wrapping up a productive Q4 meeting with our team joining from both in-person and virtually! Excited for the road ahead as we continue advancing genomic medicine together. #constantiambiosciences #team #q4meeting

At a recent workshop we attended, participants discussed the future of Variants of Uncertain Significance (VUS) and whether they would be obsolete by 2030. The consensus? Most experts disagreed. This underscores the ongoing challenge of VUS in genetic testing and highlights the critical role of tools like MAVEvidence in providing clarity. As VUS remain a significant hurdle in clinical genetics, platforms like MAVEvidence are more important than ever. By offering clear, actionable insights based on comprehensive data, MAVEvidence helps clinicians and researchers tackle genetic uncertainty and make informed decisions—ensuring that advancements in precision medicine continue beyond 2030. #MAVEvidence #GeneticTesting #VUS #PrecisionMedicine #ConstantiamBiosciences #HealthcareInnovation #Genomics

Every patient deserves clear answers and certainty, especially when it comes to their health. At Constantiam Biosciences, we empower clinicians to make accurate, informed diagnoses by resolving Variants of Uncertain Significance (VUS). With over 187,000 pieces of evidence across 125,000 variants, MAVEvidence transforms genetic ambiguity into actionable insights, providing clinicians the tools they need to reduce diagnostic uncertainty and deliver precise patient care. Together, we’re bridging the gap between genetic testing and the clarity patients deserve. #Constantiambiosciences #Mavevidence #VUS #patientcare

We’re thrilled to share that the findings from the Clinical Application of MAVE Data Workshop, which our team had the privilege of attending, have been published in the European Journal of Human Genetics! The paper highlights key discussions on integrating Multiplexed Assays of Variant Effect (MAVEs) into clinical variant classification, addressing challenges like standardized validation, model organism selection, and data accessibility. As participants largely disagreed that VUS would be obsolete by 2030, this highlights the continued importance of MAVEs in addressing the challenges of VUS well beyond 2030, ensuring their critical role in variant classification for years to come. #constantiambiosciences #MAVES

At Constantiam Biosciences, we understand the emotional and clinical burden that Variants of Uncertain Significance (VUS) bring. Our MAVEvidence platform is designed to tackle these challenges head-on, transforming genetic ambiguity into clear, actionable insights. By providing clinicians with reliable data, we help resolve VUS, offering patients the clarity they deserve on their health journey. #GeneticTesting #MAVEvidence #PrecisionMedicine #VUS #HealthcareInnovation #ConstantiamBiosciences

Constantiam Biosciences is proud to announce that we have been awarded a $2.05 million Phase II SBIR grant from the (National Human Genome Research Institute (NHGRI). This funding will support the continued development of our cutting-edge platforms, Varify™ and MAVEvidence™, designed to enhance the accuracy of genetic variant interpretation and accelerate drug discovery. This milestone brings us closer to our mission of advancing precision medicine by providing innovative solutions that transform genetic testing and improve patient outcomes. Learn more about our exciting developments: [https://lnkd.in/dKSRwY8m]

As my summer internship at Constantiam Biosciences sadly has come to an end, I am excited to share some of the incredible experiences I’ve gathered over these past few months. Joining as a Business Development intern for the summer, I had the opportunity to work directly alongside the incredibly talented team behind Constantiam and contribute to key efforts in moving the company forward. Including reworking strategy & pitching materials as well as setting up and conducting meetings with people from a long range of international and Boston-based biotech companies such as Takeda, BioInvent, Merck, Eli Lilly, Ginko BioWorks and Dyno Therapeutics, with a high level of freedom and initiative to do so! I also want to thank everyone I have met in this process for being incredibly kind and generous with their time! This first-hand experience of working at a Biotech start-up has given me a deep dive into the industries drug discovery process and genetic variation analysis, as well as practical experience with pitching and a great opportunity to network, meeting some really impressive people along the way. A huge thank you to the entire Constantiam Team for their guidance, support, and for providing an environment where I felt encouraged to challenge myself (and them at times). I am excited to apply what I’ve learned in my future endeavours, and looking forward to staying connected with the wonderful people I met and to seeing how we might hopefully cross paths again in the future!